Palliating influenza

Patients who forget their flu shots may have two treatments to choose from in the forseeable future. The next question will be how much insurers and patients will pay to be less sick for a shorter time.

At last week's Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego, F. Hoffmann-La Roche Ltd. presented Phase III data on partner Gilead Sciences Inc.'s GS 4104 influenza treatment, while Glaxo Wellcome plc presented data from a Phase III Australian trial of partner Biota Holdings Ltd.'s Relenza zanamivir GG167.